Brokerages Set Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Price Target at $21.15

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) has been given a consensus rating of “Buy” by the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $21.15.

A number of brokerages recently commented on ALDX. Laidlaw reiterated a “buy” rating and issued a $30.00 target price on shares of Aldeyra Therapeutics in a research report on Tuesday, May 26th. Janney Montgomery Scott reiterated a “market perform” rating and issued a $28.00 target price on shares of Aldeyra Therapeutics in a research report on Tuesday, May 26th. Oppenheimer assumed coverage on shares of Aldeyra Therapeutics in a research report on Wednesday, May 20th. They issued a “buy” rating and a $12.00 price objective on the stock. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research report on Monday, March 30th. Finally, ValuEngine cut shares of Aldeyra Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 11th.

In other news, Director Richard Douglas acquired 40,000 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were purchased at an average price of $2.75 per share, for a total transaction of $110,000.00. Following the completion of the transaction, the director now owns 125,000 shares of the company’s stock, valued at $343,750. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.50% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new stake in Aldeyra Therapeutics during the fourth quarter worth about $29,000. Spark Investment Management LLC bought a new stake in Aldeyra Therapeutics during the first quarter worth about $40,000. Tower Research Capital LLC TRC boosted its stake in Aldeyra Therapeutics by 204.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,981 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 4,688 shares in the last quarter. Citigroup Inc. boosted its stake in Aldeyra Therapeutics by 64.6% during the fourth quarter. Citigroup Inc. now owns 9,298 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 3,649 shares in the last quarter. Finally, SlateStone Wealth LLC bought a new stake in Aldeyra Therapeutics during the fourth quarter worth about $70,000. 56.35% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:ALDX traded down $0.07 during trading hours on Tuesday, reaching $4.98. The company’s stock had a trading volume of 1,054,434 shares, compared to its average volume of 459,442. The firm has a market capitalization of $146.57 million, a price-to-earnings ratio of -2.50 and a beta of 2.10. The firm has a 50-day simple moving average of $3.40 and a 200-day simple moving average of $4.50. Aldeyra Therapeutics has a 1 year low of $1.48 and a 1 year high of $8.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 12.84 and a current ratio of 12.84.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.14. Equities analysts anticipate that Aldeyra Therapeutics will post -1.41 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

See Also: What is the Current Ratio?

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.